Tryton Medical to Present Pivotal Clinical Data on Dedicated Bifurcation Stent at TCT 2015

Dateline City:

Company will host lunch symposium to highlight implications of findings on treatment of coronary bifurcation lesions on Tuesday, October 13th at 11:30am PDT.

DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat
coronary bifurcation lesions, today announced the company will present
results from the Tryton Confirmatory Study, a pivotal single-arm
clinical trial evaluating use of the Tryton Side Branch Stent in
patients with coronary bifurcation lesions involving side branches that
are 2.25mm in diameter or greater. Results will be presented at
Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific
symposium of the Cardiovascular Research Foundation (CRF) to be held
October 11-15, 2015 in San Francisco, Calif.

Tryton Confirmatory Study results will be presented by Dr. Philippe
Généreux, director of the Angiographic Core Laboratory at the CRF
Clinical Trials Center, as part of the “Featured Clinical Research I:
Presentations to the Editors of the Journal of the American College
of Cardiology
” session on Monday, October 12th at 1:30pm

Tryton will also host a lunch symposium to review the findings and the
implications for clinical practice on Tuesday, October 13th
at 11:30am PDT. The symposium will be co-chaired by Dr. Martin Leon,
director of the Center for Interventional Vascular Therapy at Columbia
University Medical Center, New York-Presbyterian Hospital, and Dr. Dean
Kereiakes, medical director for the Christ Hospital Heart and Vascular
Center and the Carl and Edyth Lindner Center for Research and Education.

In addition, the Tryton Side Branch Stent will be the subject of a case
study presentation and a number of poster abstracts during the meeting.
The complete schedule for Tryton at TCT 2015 is as follows:

Monday, October 12

  • Featured Clinical Research, 1:30pm – 1:40pm PDT
    Moscone South,
    Lower Level, Room 104
    The TRYTON PIVOTAL: Randomized Trial and
    Confirmatory Study
    Dedicated Bifurcation Stent in Coronary
    Bifurcation Involving Large Side Branches
  • Dedicated Systems for Specific Lesion Subsets, 5:03pm – 6:10pm PDT
    West, 3rd Floor, Room 3001 – 3005
    Case 5: Bifurcations or Left
    Main – The Tryton Stent

Tuesday, October 13

  • Tryton Lunch Symposium, 11:30am – 12:30pm PDT
    Moscone South,
    Lower Level, Exhibit Hall, Presentation Theater 4
    Randomized Trial and Confirmatory Study
    Implications for
    Everyday Practice
  • Poster abstracts, 4:00pm – 6:00pm PDT
    Moscone West, 1st Floor
  • 2-Year Clinical Follow-up of the TRYTON IDE Randomized Trial
  • Incidence of Peri-Procedural MI: Insight from the Tryton IDE
    Randomized Trial
  • Detailed Segmental Comparison Using IVUS and 3D QCA: a Subgroup
    Analysis of the Tryton IDE Randomized Trial

Wednesday, October 14

  • Next Generation DES Technology: Let the Future Begin! 6:00pm – 8:00pm
    Ballroom Level, Continental Ballroom 1-4
    Stents to Treat Different Anatomical and Clinical Scenarios
    MI, Small Vessels, and More

Tryton will also be exhibiting at booth #1317. For news and updates from
Tryton throughout TCT 2015, follow @TrytonMedical1
and the hashtag #BuiltForBifurcation on Twitter.

About Tryton Side Branch Stent

Tryton Side Branch Stent System is built using proprietary Tri-ZONE®
technology to offer a dedicated strategy for treating bifurcation
lesions. Tryton’s cobalt chromium stent is deployed in the side branch
artery using a standard single wire balloon-expandable stent delivery
system. A conventional drug eluting stent is then placed in the main
vessel. Tryton Side Branch Stent has now been used to treat more than
11,000 patients worldwide. The Tryton Side Branch Stent is commercially
available in multiple countries within Europe, Middle East & Africa, is
investigational in the US, and is not available in Japan.

About Tryton Medical, Inc.

Tryton Medical, Inc., located in Durham, N.C., is the leading developer
of novel stent systems for the treatment of bifurcation lesions. The
company was founded in 2003 by Aaron V. Kaplan, M.D., professor of
medicine at Dartmouth Medical School/Dartmouth-Hitchcock Medical Center,
to develop stents for the definitive treatment of bifurcation lesions.
For more information please visit
and follow the company on Twitter at @TrytonMedical1.



Tryton Medical, Inc.
Judy Gonzalez, 919-226-1490